PHASE 2 STUDY TO EVALUATE THE CLINICAL EFFICACY AND SAFETY OF MEDI4736 (DURVALUMAB, DURVA) plus BEVACIZUMAB (BEV) IN BEV-NAIVE PATIENTS WITH RECURRENT GLIOBLASTOMA (GBM)

被引：0
|
作者：
Reardon, David [1 ]
Kaley, Thomas [2 ]
Dietrich, Jorg [3 ]
Clarke, Jennifer [4 ]
Dunn, Gavin [5 ]
Lim, Michael [6 ]
Cloughesy, Tim [7 ]
Gan, Hui [8 ]
Park, Andrew [9 ]
Schwarzenberger, Paul [9 ]
Ricciardi, Toni [9 ]
Macri, Mary [9 ]
Ryan, Aileen [9 ]
Venhaus, Ralph [9 ]
机构：
[1] Dana Farber Canc Inst, Ctr Neurooncol, Boston, MA 02115 USA
[2] Mem Sloan Kettering Canc Ctr, 1275 York Ave, New York, NY 10021 USA
[3] Massachusetts Gen Hosp, Boston, MA 02114 USA
[4] Univ Calif San Francisco, San Francisco, CA 94143 USA
[5] Washington Univ, St Louis, MO USA
[6] Johns Hopkins Univ Hosp, Baltimore, MD 21287 USA
[7] Univ Calif Los Angeles, Neurooncol, Los Angeles, CA USA
[8] Austin Hosp, Melbourne, ACT, Australia
[9] Ludwig Inst Canc Res, New York, NY USA
来源：
NEURO-ONCOLOGY | 2018年 / 20卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
ATIM-38
引用
收藏
页码：10 / 10
页数：1
相关论文
共 50 条
  • [1] PHASE 2 STUDY TO EVALUATE THE CLINICAL EFFICACY AND SAFETY OF MEDI4736 (DURVALUMAB [DUR]) IN PATIENTS WITH BEVACIZUMAB (BEV)-REFRACTORY RECURRENT GLIOBLASTOMA (GBM)
    Reardon, David
    Kaley, Thomas
    Dietrich, Jorg
    Clarke, Jennifer L.
    Dunn, Gavin P.
    Lim, Michael
    Cloughesy, Timothy
    Gan, Hui K.
    Park, Andrew
    Schwarzenberger, Paul
    Ricciardi, Toni
    Macri, Mary
    Ryan, Aileen
    Venhaus, Ralph
    NEURO-ONCOLOGY, 2017, 19 : 28 - 28
  • [2] PHASE 2 STUDY TO EVALUATE THE CLINICAL EFFICACY AND SAFETY OF MEDI4736 (DURVALUMAB [DUR]) IN PATIENTS WITH GLIOBLASTOMA (GBM): RESULTS FOR COHORT B (DUR MONOTHERAPY), BEVACIZUMAB (BEV) NAIVE PATIENTS WITH RECURRENT GBM
    Reardon, David
    Kaley, Thomas
    Dietrich, Jorg
    Lim, Michael
    Dunn, Gavin
    Gan, Hui
    Cloughesy, Timothy
    Clarke, Jennifer
    Park, Andrew
    Macri, Mary
    Ryan, Aileen
    Ricciardi, Toni
    Reddy, Vijay
    Venhaus, Ralph
    NEURO-ONCOLOGY, 2016, 18 : 18 - 18
  • [3] Phase 2 study to evaluate the clinical efficacy and safety of MEDI4736 (durvalumab) in patients with glioblastoma (GBM).
    Reardon, David A.
    Kaley, Thomas Joseph
    Dietrich, Jorg
    Lim, Michael
    Dunn, Gavin P.
    Gan, Hui Kong
    Cloughesy, Timothy Francis
    Clarke, Jennifer Leigh
    Park, Andrew J.
    Macri, Mary J.
    Ryan, Aileen
    Ricciardi, Toni
    Reddy, Vijay
    Venhaus, Ralph Rudolph
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [4] Phase II study to evaluate the clinical efficacy and safety of MEDI4736 (durvalumab) in patients with glioblastoma (GBM): Results for cohort B (durvalumab monotherapy), bevacizumab-naive patients with recurrent GBM
    Reardon, David A.
    Kaley, Thomas
    Dietrich, Jorg
    Lim, Michael
    Dunn, Gavin P.
    Gan, Hui K.
    Cloughesy, Timothy
    Clarke, Jennifer L.
    Park, Andrew
    Macri, Mary
    Ryan, Aileen
    Ricciardi, Toni
    Reddy, Vijay
    Venhaus, Ralph
    CANCER IMMUNOLOGY RESEARCH, 2016, 4 (11)
  • [5] Phase 2 study to evaluate the clinical efficacy and safety of MEDI4736 in patients with glioblastoma (GBM)
    Reardon, David A.
    Dietrich, Jorg
    Kaley, Thomas
    Gan, Hui
    Dunn, Gavin P.
    Cloughesy, Timothy
    Lim, Michael
    Clarke, Jennifer
    Park, Andrew
    Pang, Linda
    Lai, Domenic W.
    Karakunnel, Joyson
    Robbins, Paul
    Narwal, Rajesh
    Venhaus, Ralph
    CANCER IMMUNOLOGY RESEARCH, 2016, 4 (01)
  • [6] Phase II study to evaluate the clinical efficacy and safety of MEDI4736 in patients with glioblastoma (GBM).
    Reardon, David A.
    Dietrich, Jorg
    Kaley, Thomas Joseph
    Gan, Hui Kong
    Dunn, Gavin P.
    Cloughesy, Timothy Francis
    Lim, Michael
    Clarke, Jennifer Leigh
    Park, Andrew J.
    Pan, Linda S.
    Lai, Dominic W.
    Karakunnel, Joyson Joseph
    Robbins, Paul B.
    Narwal, Rajesh
    Venhaus, Ralph Rudolph
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [7] Phase 2 study to evaluate safety and efficacy of MEDI4736 (durvalumab [DUR]) in glioblastoma (GBM) patients: An update.
    Reardon, David A.
    Kaley, Thomas Joseph
    Dietrich, Jorg
    Clarke, Jennifer Leigh
    Dunn, Gavin P.
    Lim, Michael
    Cloughesy, Timothy Francis
    Gan, Hui Kong
    Park, Andrew J.
    Schwarzenberger, Paul
    Ricciardi, Toni
    Macri, Mary J.
    Ryan, Aileen
    Venhaus, Ralph Rudolph
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [8] Phase II study to evaluate safety and efficacy of MEDI4736 (durvalumab) plus radiotherapy in patients with newly diagnosed unmethylated MGMT glioblastoma (new unmeth GBM).
    Reardon, David A.
    Kaley, Thomas Joseph
    Dietrich, Jorg
    Clarke, Jennifer Leigh
    Dunn, Gavin
    Lim, Michael
    Cloughesy, Timothy Francis
    Gan, Hui Kong
    Park, Andrew J.
    Schwarzenberger, Paul
    Ricciardi, Toni
    Macri, Mary J.
    Ryan, Aileen
    Venhaus, Ralph Rudolph
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [9] Phase 1 study to evaluate the safety and tolerability of MEDI4736 (durvalumab, durva) plus tremelimumab (treme) in patients with advanced solid tumors
    Callahan, Margaret K.
    Odunsi, Kunle
    Sznol, Mario
    Nemunaitis, John
    Ott, Patrick A.
    Dillon, Patrick
    Schneider, Reva
    Park, Andrew
    Schwarzenberger, Paul
    Ricciardi, Toni
    Macri, Mary
    Ryan, Aileen
    Venhaus, Ralph
    Wolchok, Jedd D.
    CANCER IMMUNOLOGY RESEARCH, 2019, 7 (02)
  • [10] Phase 1 study to evaluate the safety and tolerability of MEDI4736 (durvalumab, DUR) plus tremelimumab (TRE) in patients with advanced solid tumors.
    Callahan, Margaret K.
    Odunsi, Kunle
    Sznol, Mario
    Nemunaitis, John J.
    Ott, Patrick Alexander
    Dillon, Patrick Michael
    Park, Andrew J.
    Schwarzenberger, Paul
    Ricciardi, Toni
    Macri, Mary J.
    Ryan, Aileen
    Venhaus, Ralph Rudolph
    Wolchok, Jedd D.
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
12345